SS
ATRA icon

SBI Securities’s Atara Biotherapeutics ATRA Stock Holding History

SBI Securities’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1K Sell
1,404
-170
-11% -$1.36K ﹤0.01% 1629
2026
Q1 		$7.45K Buy
1,574
+170
+12% +$1.04K ﹤0.01% 1864
2025
Q4 		$25.4K Hold
1,404
– – ﹤0.01% 1347
2025
Q3 		$20.1K Hold
1,404
– – ﹤0.01% 1450
2025
Q2 		$10.8K Hold
1,404
– – ﹤0.01% 1676
2025
Q1 		$8.34K Sell
1,404
-12
-0.8% -$105 ﹤0.01% 1677
2024
Q4 		$18.8K Buy
+1,416
New +$14.9K ﹤0.01% 1381

Other funds holding ATRA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SBI Securities's ATRA Position: Q2 2026 in Review

SBI Securities reduced its Atara Biotherapeutics (ATRA) stake by 11% in Q2 2026, selling an estimated $1.36K and leaving 1,404 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1629.

SBI Securities first reported a position in ATRA in Q4 2024 and has held it in 7 quarters since. The position peaked at $25.4K in Q4 2025. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • SBI Securities held 1,404 shares of Atara Biotherapeutics worth $16.1K as of Q2 2026.
  • SBI Securities sold 170 Atara Biotherapeutics shares in Q2 2026, an estimated $1.36K.
  • Atara Biotherapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1629 holding.
  • SBI Securities first reported a position in Atara Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Atara Biotherapeutics position peaked at $25.4K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.